clinical trial · NCT05067257
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Sorrento Therapeutics, Inc.·phase2·suspended·n = 120
Pain, IntractablePain CancerPainResiniferatoxinPlacebo
brief summary
This Phase 2 study assesses the safety and efficacy of a single injection of Resiniferatoxin versus placebo for the treatment of intractable advanced cancer pain.
started
Sep 1, 2025
primary completion
Jun 1, 2027
completion
Dec 1, 2027
last updated
Mar 18, 2024
detailed description
This is a global multicenter, randomized Phase 2 study for subjects with advanced cancer experiencing intractable pain to assess the safety and efficacy of a single epidural injection of Resiniferatoxin versus vehicle control. Additional subjects who elect to not enroll but are willing to be followed will comprise a Concurrent Control Group. Subjects will be followed for twelve months.
official title
A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol